HPV detection in first void urine and cervicovaginal samples: comparative study and analysis of associated factors in women from Tunja, Colombia

To compare Human Papillomavirus (HPV) detection in first-void urine (FVU) and cervicovaginal samples and to analyze factors associated with cervicovaginal HPV infection among women in Tunja, Colombia. A cross-sectional study was conducted among 161 women aged 20–65 years residing in Tunja, Colombia. Samples and data were collected between September and November 2022 in a clinical laboratory. Cervicovaginal and FVU samples were obtained for HPV genotyping using the INNO-LiPA HPV Genotyping Extra II kit. Concordance, sensitivity, specificity, and associations with sociodemographic and gynecological variables were evaluated. Crude and adjusted odds ratios (OR) were estimated using logistic regression. HPV prevalence was 29.19% in cervicovaginal samples and 32.91% in urine samples. Genotypes 52 and 68 were the most frequent in both sample types. Concordance between tests was weak (kappa = 0.39). Sensitivity and specificity of urine-based detection were 61.70% and 78.94%, respectively. In the multivariable model, only pregnancy history remained independently associated with cervicovaginal HPV infection. HPV infection prevalence was moderate, with high-risk genotypes detected in both sample types. The history of pregnancy was the only independent factor associated with cervicovaginal HPV infection. HPV detection in urine showed limited diagnostic performance, highlighting the need to optimize urine screening strategies. • Urine and cervicovaginal samples showed similar human papillomavirus detection. • High risk genotypes were common in urine and cervicovaginal samples. • Urine testing showed limited agreement with cervicovaginal results. • Sexual and reproductive factors were linked to cervicovaginal infection. • Pregnancy history remained associated after multivariable adjustment.